Andre-Guy Martin

Dr. Andre-Guy Martin

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in European Urology
Verified
Journal Article
Closed access
ANAbdenour Nabid
Abdenour Nabid
NCNathalie Carrier
Nathalie Carrier
AMAndre-Guy Martin
Andre-Guy Martin
JBJean-Paul Bahary
Jean-Paul Bahary
CLCéline Lemaire
Céline Lemaire
LSLuis Souhami
Luis Souhami

1 March 2009 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
FBFrançois Bachand
François Bachand
AMAndre-Guy Martin
Andre-Guy Martin
LBLuc Beaulieu
Luc Beaulieu
FHFrançois Harel
François Harel
ÉVÉric Vigneault
Éric Vigneault

1 March 2015 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
GSGraham D. Smith
Graham D. Smith
TPTom Pickles
Tom Pickles
JCJuanita Crook
Juanita Crook
AMAndre-Guy Martin
Andre-Guy Martin
EVEric Vigneault
Eric Vigneault
GRGeorge Rodrigues
George Rodrigues

1 July 2007 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
JCJean-François Carrier
Jean-François Carrier
MDMichel D’aMours
Michel D’aMours
FVFrank Verhaegen
Frank Verhaegen
BRBrigitte RENIERS
Brigitte RENIERS
AMAndre-Guy Martin
Andre-Guy Martin
LBLuc Beaulieu
Luc Beaulieu

28 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
AGAurelie Garant
Aurelie Garant
CVCarol-Ann Vasilevsky
Carol-Ann Vasilevsky
MBMarylise Boutros
Marylise Boutros
FKFarzin Khosrow-Khavar
Farzin Khosrow-Khavar
PKPetr Kavan
Petr Kavan
Te VuongTe Vuong
Te Vuong
Background: We explored image-guided adaptive endorectal brachytherapy patients electing non-operative management for rectal cancer. We present the first pre-planned interim analysis. Methods: In this open-label phase II–III randomized study, patients with operable cT2-3ab N0 M0 rectal cancer received 45 Gy in 25 fractions of pelvic external beam radiotherapy (EBRT) with 5-FU/Capecitabine. They were randomized 1:1 to receive either an EBRT boost of 9 Gy in 5 fractions (Arm A) or three weekly adaptive brachytherapy (IGAEBT) boosts totaling 30 Gy (Arm B). Patient characteristics and toxicity are presented using descriptive analyses; TME-free survival between arms with the intention to treat the population is explored using the Kaplan–Meier method. Results: A total of 40 patients were in this analysis. Baseline characteristics were balanced; acute toxicities were similar. Complete clinical response (cCR) was 50% (n = 10/20) in Arm A and 90% in Arm B (n = 18/20). Median follow-up was 1.3 years; 2-year TME-free survival was 38.6% (95% CI: 16.5–60.6%) in the EBRT arm and 76.6% (95% CI: 56.1–97.1%) in the IGAEBT arm. Conclusions: Radiation intensification with IGAEBT is feasible. This interim analysis suggests an improvement in TME-free survival when comparing IGAEBT with EBRT, pending confirmation upon completion of this trial.

1 February 2007 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
AMAndre-Guy Martin
Andre-Guy Martin
JRJean Roy
Jean Roy
LBLuc Beaulieu
Luc Beaulieu
JPJean Pouliot
Jean Pouliot
FHFrançois Harel
François Harel
EVEric Vigneault
Eric Vigneault